EU Rejects Amgen’s EVENITY

EU Rejects Amgen’s EVENITY

The European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced it has adopted a negative opinion on EVENITY (romosozumab-aqqb), an osteoporosis drug for postmenopausal women with high fracture risk. The U.S. FDA approved the Amgen...

Pin It on Pinterest